Latest Attention-deficit hyperactivity disorder controversies Stories

FLORHAM PARK, N.J., Jan. 10, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY(TM), an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. KAPVAY(TM) is the first and only FDA-approved ADHD treatment indicated for use as add-on...

Brain scans of children with attention-deficit/hyperactivity disorder (ADHD) have shown for the first time why people affected by the condition sometimes have difficulty in concentrating. The study, by experts at The University of Nottingham, may explain why parents often say that their child can maintain concentration when they are doing something that interests them, but struggles with boring tasks.Using a 'Whac-a-Mole' style game, researchers from the Motivation, Inhibition and Development...

Brain scans of children with attention-deficit/hyperactivity disorder (ADHD) have shown for the first time why people affected by the condition sometimes have such difficulty in concentrating. The study, funded by the Wellcome Trust, may explain why parents often say that their child can maintain concentration when they are doing something that interests them, but struggles with boring tasks.Using a 'Whac-a-Mole' style game, researchers from the Motivation, Inhibition and Development in ADHD...

PHILADELPHIA, Dec. 20, 2010 /PRNewswire-USNewswire/ -- For doctors and parents to jointly decide how to attack pediatric conditions, such as attention-deficit/hyperactivity disorder (ADHD), practical barriers to recommended health treatments need to be overcome, according to a study by The Children's Hospital of Philadelphia. In considering their options, parents preferred their physicians to offer an unbiased presentation of all available treatments. The study, published online today in...

(Ivanhoe Newswire) "“ On the surface, children with fetal alcohol exposure and attention deficit hyperactivity disorder (ADHD) appear to have similar symptoms and issues, but this study shows that each disorder appears to affect different areas of the brain.The researchers used number processing to show that difference in brain stimulation, and the results shows that the treatments for one might not be effective for the other, meaning there's a need to create tailor-made interventions for...

Children with ADHD can sometimes have more difficulties on math and reading tests compared to their peers. A new study published in Psychological Science, a journal of the Association for Psychological Science, used identical and fraternal twins to look at the genetic and environmental influences underlying ADHD behaviors, reading, and math skills in children in an attempt to better understand the relationship among them. Sara Hart, of the Florida State University, and her colleagues used...

Whatever its final incarnation, the recently enacted landmark Patient Protection and Affordable Care Act will expand Medicaid eligibility and is expected by 2013 to provide coverage, including mental health care, to an estimated 4.1 million children currently uninsured.That's a good thing. But what will the quality of care be, especially for vulnerable children with special health care needs? Poor, according to a new report in the current online edition of the Journal of the American Academy...

The enactment of the Patient Protection and Affordable Care Act of 2010 expands Medicare benefits to scores of previously uninsured individuals including many of our nation's children. While access to treatment is laudable, the quality of such treatment is the subject of an article in the December issue of the Journal of the American Academy of Child and Adolescent Psychiatry.In the article titled "Quality of Care for Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) in a Managed...

PHILADELPHIA, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to...

A government survey shows that 1 in 10 children in the U.S. have ADHD, which is an increase from a few years earlier. Attention deficit hyperactivity disorder, ADHD, makes it hard for kids to pay attention and control impulsive behavior.  The study found that about two-thirds of children with the condition are on medication.  The researchers believe that growing awareness and better screening might be the reason for the increase. The new study found an increase in ADHD of about 22...